Metacrine Inc. (MTCR) Social Stream

Featured Post From StockTwits About MTCR

$MTCR has 1 site of 1 active in its 28-day MET642 (FXR agonist) study (n=180) and 2 active sites for its 28-day MET409 (FXR agonist) study (n=120), whose topline data in Jan. 2022 and Apr. 2022, respectively, will help a decision in candidate selection for a Phase 2b NASH biopsy as early as 2H21. If MET409 is selected, a study will initiate by YE21 and MET642 will initiate in 1H22.